Immunotherapy
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global immunotherapy market insights. NovaPharmaNews delivers critical intelligence for pharma BD, investors & analysts. Stay ahead.
Showing 1–12 of 14 articles
Quick answer
NovaPharmaNews Immunotherapy hub for FDA covers 14 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds
Tempest Therapeutics TPST-2003 CAR-T Shows Promise for Multiple Myeloma at ISCT 2026
AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
ACRP 2026: Immunology Clinical Research Highlights - Day 1
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Anktiva Claims
Greenwich LifeSciences GLSI-100 Abstract Accepted at ASCO 2026 for Breast Cancer Immunotherapy Trial
Tempest Therapeutics Achieves Manufacturing Milestone for TPST-2003 CAR-T Cancer Treatment
Mabwell 9MW2821 Combination Therapy Data to Be Presented at ASCO 2026 for Urothelial Carcinoma Treatment
AACR 2026: ctDNA, Immunotherapy, and KRAS Target Breakthroughs
Innovent Biologics IBI363 Clinical Data to Be Presented at ASCO 2026 Annual Meeting
AACR 2024: Oncology Research Highlights - Day 1 Roundup
AACR 2026: Myocarditis Risk, KRAS Inhibitors, mRNA Advances
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.